Suicide gene therapy in cancer: Where do we stand now?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/24816 https://doi.org/10.1016/j.canlet.2012.05.023 |
Resumo: | Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance. However, recent reports on pre-clinical cancer models demonstrate the huge potential of this strategy when used in combination with new therapeutic approaches. In this review, we summarize the different suicide gene systems and gene delivery vectors addressed to cancer, with particular emphasis on recently developed systems and associated bystander effects. In addition, we review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach, particularly towards cancer stem cell eradication. |
id |
RCAP_623ed8e4ef944d2fd3f92aa381b2427e |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/24816 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Suicide gene therapy in cancer: Where do we stand now?Suicide gene therapyCancerBystander effectCombined strategiesSuicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance. However, recent reports on pre-clinical cancer models demonstrate the huge potential of this strategy when used in combination with new therapeutic approaches. In this review, we summarize the different suicide gene systems and gene delivery vectors addressed to cancer, with particular emphasis on recently developed systems and associated bystander effects. In addition, we review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach, particularly towards cancer stem cell eradication.Elsevier2012-11info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/24816http://hdl.handle.net/10316/24816https://doi.org/10.1016/j.canlet.2012.05.023engDUARTE, Sónia [et al.] - Suicide gene therapy in cancer: Where do we stand now?. "Cancer Letters". ISSN 0304-3835. 324:2 (2012) 160-1700304-3835http://www.sciencedirect.com/science/journal/03043835Duarte, SóniaCarle, GeorgesFaneca, HenriqueLima, Maria C. Pedroso dePierrefite-Carle, Valérieinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2021-09-17T11:05:02Zoai:estudogeral.uc.pt:10316/24816Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:53:34.841862Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Suicide gene therapy in cancer: Where do we stand now? |
title |
Suicide gene therapy in cancer: Where do we stand now? |
spellingShingle |
Suicide gene therapy in cancer: Where do we stand now? Duarte, Sónia Suicide gene therapy Cancer Bystander effect Combined strategies |
title_short |
Suicide gene therapy in cancer: Where do we stand now? |
title_full |
Suicide gene therapy in cancer: Where do we stand now? |
title_fullStr |
Suicide gene therapy in cancer: Where do we stand now? |
title_full_unstemmed |
Suicide gene therapy in cancer: Where do we stand now? |
title_sort |
Suicide gene therapy in cancer: Where do we stand now? |
author |
Duarte, Sónia |
author_facet |
Duarte, Sónia Carle, Georges Faneca, Henrique Lima, Maria C. Pedroso de Pierrefite-Carle, Valérie |
author_role |
author |
author2 |
Carle, Georges Faneca, Henrique Lima, Maria C. Pedroso de Pierrefite-Carle, Valérie |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Duarte, Sónia Carle, Georges Faneca, Henrique Lima, Maria C. Pedroso de Pierrefite-Carle, Valérie |
dc.subject.por.fl_str_mv |
Suicide gene therapy Cancer Bystander effect Combined strategies |
topic |
Suicide gene therapy Cancer Bystander effect Combined strategies |
description |
Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance. However, recent reports on pre-clinical cancer models demonstrate the huge potential of this strategy when used in combination with new therapeutic approaches. In this review, we summarize the different suicide gene systems and gene delivery vectors addressed to cancer, with particular emphasis on recently developed systems and associated bystander effects. In addition, we review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach, particularly towards cancer stem cell eradication. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-11 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/24816 http://hdl.handle.net/10316/24816 https://doi.org/10.1016/j.canlet.2012.05.023 |
url |
http://hdl.handle.net/10316/24816 https://doi.org/10.1016/j.canlet.2012.05.023 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
DUARTE, Sónia [et al.] - Suicide gene therapy in cancer: Where do we stand now?. "Cancer Letters". ISSN 0304-3835. 324:2 (2012) 160-170 0304-3835 http://www.sciencedirect.com/science/journal/03043835 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133822332174336 |